Photosoft compounds showed activity in vitro against multiple strains of antibiotic-resistant MRSA bacteria, Escherichia coli bacteria and Candida albicans fungus in tests undertaken at the Australian Centre for Antimicrobial Resistance Ecology (ACARE), University of Adelaide. MRSA is an antibiotic-resistant bacterium that is difficult to treat, with the World Health Organisation (WHO) having declared antimicrobial resistance…
Read more
Photosoft shows activity against Dengue in Preliminary Assay
Eight out of Ten Photosoft compounds showed antiviral activity against the Dengue virus after exposure to light. The eight compounds have superior Therapeutic Index (TI) values to Monensin. The most effective compound had an EC50 (half maximal effective concentration) value that is >90 times lower than Monensin (control drug). No compound displayed antiviral activity when…
Read more
Hudson Institute to Present Photosoft at Combio2022
Hudson Institute of Medical Research (Hudson Institute) is presenting a poster on the Photosoft technology at the prestigious ComBio2022 industry conference to be held in Melbourne from 27-30th September 2022. ComBio is the Australian Society for Biochemistry and Molecular Biology's (ASBMB's) national biennial conference, which runs in conjunction with other societies and features world renowned…
Read more
INV043 Effective Against Anal Cancer SCC In Vitro
In vitro study by Peter Mac showed INV043's effectiveness against six squamous cell carcinoma (SCC) cell lines that represent the full range of anal cancers. Most anal cancers are SCCs and are difficult to treat with the global market estimated to be worth US$1.3bn by 2028 (6.3% CAGR). The Peter Mac study added another clinically…
Read more